The project offers the opportunity to improve the five year survival rate or even cure pancreatic cancer with a new treatment paradigm. We will use anti-mesothelin (MSLN) chimeric antigen receptor (CAR) T-cells in a trial to test their effectiveness in improving health outcomes for patients who have received the devastating diagnosis of pancreatic cancer.